Subscribe
shutterstock_1010946472_nitpicker-1
nitpicker / Shutterstock.com
22 March 2019Big Pharma

CJEU puts further brakes on SPCs

The Court of Justice of the European Union (CJEU) yesterday, March 21, handed down a supplementary protection certificate (SPC) decision referred to it by the English High Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
Questions on Neurim scope remain post-SPC ruling, say lawyers
25 March 2019   The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
Big Pharma
CJEU hands down SPC guidance in Royalty Pharma
30 April 2020   The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
Questions on Neurim scope remain post-SPC ruling, say lawyers
25 March 2019   The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
Big Pharma
CJEU hands down SPC guidance in Royalty Pharma
30 April 2020   The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.

More on this story

Big Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
Questions on Neurim scope remain post-SPC ruling, say lawyers
25 March 2019   The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
Big Pharma
CJEU hands down SPC guidance in Royalty Pharma
30 April 2020   The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court